BioCentury
ARTICLE | Financial News

Microbiome newco Axial raises $19.2M

November 30, 2016 11:44 PM UTC

Axial Biotherapeutics Inc. (Boston, Mass.) raised $19.2 million in a series A round, with which it hopes to develop microbiome-based treatments for CNS disorders. Longwood Fund and Domain Associates co-led the round. Kairos Ventures, Heritage Medical Systems and individual investors also participated.

The company is developing a microbiome discovery platform targeting the gut-brain axis based on findings from scientific founder and California Institute of Technology microbiology professor Sarkis Mazmanian linking interactions in the gut microbiome to neurological disorders. Axial has an exclusive, worldwide license to in vitro and in vivo models as well as compounds developed in Mazmanian's lab...